We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

43 hedge funds and large institutions have $454M invested in UroGen Pharma in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 7

78% more capital invested

Capital invested by funds: $254M → $454M (+$200M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

8.16% more ownership

Funds ownership: 51.88% → 60.04% (+8.2%)

5% more funds holding

Funds holding: 41 → 43 (+2)

Holders
43
Holders Change
+2
Holders Change %
+4.88%
% of All Funds
0.99%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
10
Increased
21
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$26.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$21.1M
3
EC
EcoR1 Capital
California
+$20.2M
4
CI
Clal Insurance
Israel
+$14M
5
CCM
Consonance Capital Management
New York
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$7.41M
2
SIM
Spark Investment Management
New York
-$2.63M
3
LCM
Laurion Capital Management
New York
-$1.77M
4
LSC
Lyon Street Capital
California
-$1.19M
5
HCM
Highline Capital Management
New York
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
MMH
1
Menora Mivtachim Holdings
Israel
$102M +$26.8M +535,622 +35%
CCM
2
Consonance Capital Management
New York
$57M +$11.5M +229,747 +25%
PAI
3
ProQuest Associates IV
Florida
$54.5M – – –
Wellington Management Group
4
Wellington Management Group
Massachusetts
$46.7M +$21.1M +420,785 +81%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$43M +$8.75M +174,597 +25%
MIH
6
Meitav Investment House
Israel
$22.2M +$1.73M +34,470 +8%
EC
7
EcoR1 Capital
California
$20M +$20.2M +402,300 New
HCM
8
Highline Capital Management
New York
$18.7M -$1.16M -23,077 -6%
CS
9
Credit Suisse
Switzerland
$17.5M +$6.41M +128,000 +57%
CI
10
Clal Insurance
Israel
$14.1M +$14M +279,039 +6,255%
DP
11
DSAM Partners
United Kingdom
$9.65M +$2.89M +57,750 +42%
WCM
12
Wildcat Capital Management
New York
$9.03M +$2.72M +54,389 +43%
Millennium Management
13
Millennium Management
New York
$7.91M +$7.4M +147,628 +1,285%
Renaissance Technologies
14
Renaissance Technologies
New York
$7.79M +$1.28M +25,600 +20%
Citadel Advisors
15
Citadel Advisors
Florida
$4.04M +$4.08M +81,358 New
BHB
16
Bank Hapoalim BM
Israel
$2.6M +$2.62M +52,300 New
SAM
17
Shikiar Asset Management
New York
$2.27M +$1.23M +24,550 +117%
Goldman Sachs
18
Goldman Sachs
New York
$2.22M +$1.92M +38,399 +610%
LSC
19
Lyon Street Capital
California
$1.63M -$1.19M -23,776 -42%
USAA
20
United Services Automobile Association
Texas
$1.56M +$631K +12,600 +67%
Deutsche Bank
21
Deutsche Bank
Germany
$1.47M -$1.05M -21,008 -41%
Morgan Stanley
22
Morgan Stanley
New York
$1.43M -$228K -4,555 -14%
Barclays
23
Barclays
United Kingdom
$1.24M +$1.25M +25,000 New
AA
24
ALPS Advisors
Colorado
$1.01M +$291K +5,803 +40%
CBA
25
Coastal Bridge Advisors
Connecticut
$956K -$963K -19,231 -50%
1
2 3

URGN Hedge Fund Activity: Q1 2018 in Review

43 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2018, worth a combined $454M — up 78% from $254M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new URGN positions and 8 closed out — a net gain of 2 holders — while 21 added to existing stakes and 7 trimmed.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $26.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.41M sold.

  • 43 institutional investors held UroGen Pharma (URGN) as of Q1 2018, up from 41 in Q4 2017.
  • Funds reported $454M of UroGen Pharma stock for Q1 2018, up 78% quarter-over-quarter.
  • 10 funds opened new UroGen Pharma positions in Q1 2018 and 8 closed out, a net change of +2 holders.
  • The largest UroGen Pharma buyer in Q1 2018 was Menora Mivtachim Holdings, an estimated $26.8M added.
  • The largest UroGen Pharma seller in Q1 2018 was Perceptive Advisors, an estimated $7.41M sold.

Based on aggregated 13F filings for Q1 2018.